8AQF | pdb_00008aqf

CRYSTAL STRUCTURE OF HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND LEI-515


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.55 Å
  • R-Value Free: 
    0.178 (Depositor), 0.190 (DCC) 
  • R-Value Work: 
    0.154 (Depositor), 0.170 (DCC) 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.

Jiang, M.Huizenga, M.C.W.Wirt, J.L.Paloczi, J.Amedi, A.van den Berg, R.J.B.H.N.Benz, J.Collin, L.Deng, H.Di, X.Driever, W.F.Florea, B.I.Grether, U.Janssen, A.P.A.Hankemeier, T.Heitman, L.H.Lam, T.W.Mohr, F.Pavlovic, A.Ruf, I.van den Hurk, H.Stevens, A.F.van der Vliet, D.van der Wel, T.Wittwer, M.B.van Boeckel, C.A.A.Pacher, P.Hohmann, A.G.van der Stelt, M.

(2023) Nat Commun 14: 8039-8039

  • DOI: https://doi.org/10.1038/s41467-023-43606-3
  • Primary Citation of Related Structures:  
    8AQF

  • PubMed Abstract: 

    Monoacylglycerol lipase (MAGL) regulates endocannabinoid 2-arachidonoylglycerol (2-AG) and eicosanoid signalling. MAGL inhibition provides therapeutic opportunities but clinical potential is limited by central nervous system (CNS)-mediated side effects. Here, we report the discovery of LEI-515, a peripherally restricted, reversible MAGL inhibitor, using high throughput screening and a medicinal chemistry programme. LEI-515 increased 2-AG levels in peripheral organs, but not mouse brain. LEI-515 attenuated liver necrosis, oxidative stress and inflammation in a CCl 4 -induced acute liver injury model. LEI-515 suppressed chemotherapy-induced neuropathic nociception in mice without inducing cardinal signs of CB 1 activation. Antinociceptive efficacy of LEI-515 was blocked by CB 2 , but not CB 1 , antagonists. The CB 1 antagonist rimonabant precipitated signs of physical dependence in mice treated chronically with a global MAGL inhibitor (JZL184), and an orthosteric cannabinoid agonist (WIN55,212-2), but not with LEI-515. Our data support targeting peripheral MAGL as a promising therapeutic strategy for developing safe and effective anti-inflammatory and analgesic agents.


  • Organizational Affiliation
    • Department of Molecular Physiology, Leiden University & Oncode Institute, Leiden, Netherlands.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Monoglyceride lipase323Homo sapiensMutation(s): 3 
Gene Names: MGLL
EC: 3.1.1.23
UniProt & NIH Common Fund Data Resources
Find proteins for Q99685 (Homo sapiens)
Explore Q99685 
Go to UniProtKB:  Q99685
PHAROS:  Q99685
GTEx:  ENSG00000074416 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ99685
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
NUX (Subject of Investigation/LOI)
Query on NUX

Download Ideal Coordinates CCD File 
B [auth A]1-[(~{R})-[2-chloranyl-4-[(2~{S},3~{S})-4-(3-chlorophenyl)-2,3-dimethyl-piperazin-1-yl]carbonyl-phenyl]sulfinyl]-3,3-bis(fluoranyl)pentan-2-one
C24 H26 Cl2 F2 N2 O3 S
WYHRZGBTLDYJGW-GLVLYPABSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.55 Å
  • R-Value Free:  0.178 (Depositor), 0.190 (DCC) 
  • R-Value Work:  0.154 (Depositor), 0.170 (DCC) 
Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 91.625α = 90
b = 127.568β = 90
c = 60.358γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
SADABSdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Revision History  (Full details and data files)

  • Version 1.0: 2023-08-23
    Type: Initial release
  • Version 1.1: 2025-03-12
    Changes: Database references, Structure summary